Free Trial
→ Goldman Sachs just told you what to buy (most people missed it) (From Behind the Markets) (Ad)tc pixel Free CNSL Stock Alerts

Cambridge Nutritional Sciences (CNSL) Competitors

GBX 1.81 -0.09 (-4.74%)
As of 08:43 AM Eastern
Compare

CNSL vs. CEL, BCE, OTT, FOX, and CZN

Should you buy Cambridge Nutritional Sciences stock or one of its competitors? MarketBeat compares Cambridge Nutritional Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cambridge Nutritional Sciences include Celadon Pharmaceuticals (CEL), Beacon Energy (BCE), Oxford Technology 3 Venture Capital Trust (OTT), Fox Marble (FOX), and Curzon Energy (CZN). These companies are all part of the "communication" industry.

How does Cambridge Nutritional Sciences compare to Celadon Pharmaceuticals?

Celadon Pharmaceuticals (LON:CEL) and Cambridge Nutritional Sciences (LON:CNSL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

In the previous week, Celadon Pharmaceuticals' average media sentiment score of 0.00 equaled Cambridge Nutritional Sciences'average media sentiment score.

Company Overall Sentiment
Celadon Pharmaceuticals Neutral
Cambridge Nutritional Sciences Neutral

Cambridge Nutritional Sciences has a net margin of 16.94% compared to Celadon Pharmaceuticals' net margin of -9,520.00%. Cambridge Nutritional Sciences' return on equity of 12.15% beat Celadon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Celadon Pharmaceuticals-9,520.00% -131.82% -34.40%
Cambridge Nutritional Sciences 16.94%12.15%-2.36%

Celadon Pharmaceuticals has a beta of -0.26, indicating that its share price is 126% less volatile than the broader market. Comparatively, Cambridge Nutritional Sciences has a beta of 2.101, indicating that its share price is 110% more volatile than the broader market.

10.7% of Celadon Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.6% of Cambridge Nutritional Sciences shares are owned by institutional investors. 65.1% of Celadon Pharmaceuticals shares are owned by company insiders. Comparatively, 7.8% of Cambridge Nutritional Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cambridge Nutritional Sciences has higher revenue and earnings than Celadon Pharmaceuticals. Celadon Pharmaceuticals is trading at a lower price-to-earnings ratio than Cambridge Nutritional Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celadon Pharmaceuticals£123.38K66.61-£4.97M-£7.98N/A
Cambridge Nutritional Sciences£8.06M0.53-£3.03M£0.603.02

Summary

Cambridge Nutritional Sciences beats Celadon Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does Cambridge Nutritional Sciences compare to Beacon Energy?

Cambridge Nutritional Sciences (LON:CNSL) and Beacon Energy (LON:BCE) are both small-cap communication companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

In the previous week, Cambridge Nutritional Sciences' average media sentiment score of 0.00 equaled Beacon Energy'saverage media sentiment score.

Company Overall Sentiment
Cambridge Nutritional Sciences Neutral
Beacon Energy Neutral

Cambridge Nutritional Sciences has a net margin of 16.94% compared to Beacon Energy's net margin of 0.00%. Cambridge Nutritional Sciences' return on equity of 12.15% beat Beacon Energy's return on equity.

Company Net Margins Return on Equity Return on Assets
Cambridge Nutritional Sciences16.94% 12.15% -2.36%
Beacon Energy N/A -196.88%-6.61%

Beacon Energy has lower revenue, but higher earnings than Cambridge Nutritional Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cambridge Nutritional Sciences£8.06M0.53-£3.03M£0.603.02
Beacon EnergyN/AN/A-£1.58MN/AN/A

1.6% of Cambridge Nutritional Sciences shares are owned by institutional investors. Comparatively, 5.0% of Beacon Energy shares are owned by institutional investors. 7.8% of Cambridge Nutritional Sciences shares are owned by company insiders. Comparatively, 5.9% of Beacon Energy shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cambridge Nutritional Sciences has a beta of 2.101, meaning that its stock price is 110% more volatile than the broader market. Comparatively, Beacon Energy has a beta of -0.3, meaning that its stock price is 130% less volatile than the broader market.

Summary

Cambridge Nutritional Sciences beats Beacon Energy on 7 of the 9 factors compared between the two stocks.

How does Cambridge Nutritional Sciences compare to Oxford Technology 3 Venture Capital Trust?

Oxford Technology 3 Venture Capital Trust (LON:OTT) and Cambridge Nutritional Sciences (LON:CNSL) are both small-cap communication companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

1.6% of Cambridge Nutritional Sciences shares are held by institutional investors. 7.8% of Cambridge Nutritional Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Oxford Technology 3 Venture Capital Trust's average media sentiment score of 0.00 equaled Cambridge Nutritional Sciences'average media sentiment score.

Company Overall Sentiment
Oxford Technology 3 Venture Capital Trust Neutral
Cambridge Nutritional Sciences Neutral

Oxford Technology 3 Venture Capital Trust has higher earnings, but lower revenue than Cambridge Nutritional Sciences. Oxford Technology 3 Venture Capital Trust is trading at a lower price-to-earnings ratio than Cambridge Nutritional Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford Technology 3 Venture Capital Trust-£85K0.00N/A-£2.70N/A
Cambridge Nutritional Sciences£8.06M0.53-£3.03M£0.603.02

Cambridge Nutritional Sciences has a net margin of 16.94% compared to Oxford Technology 3 Venture Capital Trust's net margin of 0.00%. Cambridge Nutritional Sciences' return on equity of 12.15% beat Oxford Technology 3 Venture Capital Trust's return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford Technology 3 Venture Capital TrustN/A N/A N/A
Cambridge Nutritional Sciences 16.94%12.15%-2.36%

Summary

Cambridge Nutritional Sciences beats Oxford Technology 3 Venture Capital Trust on 7 of the 8 factors compared between the two stocks.

How does Cambridge Nutritional Sciences compare to Fox Marble?

Cambridge Nutritional Sciences (LON:CNSL) and Fox Marble (LON:FOX) are both small-cap communication companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Cambridge Nutritional Sciences has a beta of 2.101, meaning that its share price is 110% more volatile than the broader market. Comparatively, Fox Marble has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

In the previous week, Fox Marble had 1 more articles in the media than Cambridge Nutritional Sciences. MarketBeat recorded 1 mentions for Fox Marble and 0 mentions for Cambridge Nutritional Sciences. Fox Marble's average media sentiment score of 0.67 beat Cambridge Nutritional Sciences' score of 0.00 indicating that Fox Marble is being referred to more favorably in the news media.

Company Overall Sentiment
Cambridge Nutritional Sciences Neutral
Fox Marble Positive

Fox Marble has lower revenue, but higher earnings than Cambridge Nutritional Sciences. Fox Marble is trading at a lower price-to-earnings ratio than Cambridge Nutritional Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cambridge Nutritional Sciences£8.06M0.53-£3.03M£0.603.02
Fox MarbleN/AN/A-£2.04M-£0.05N/A

Cambridge Nutritional Sciences has a net margin of 16.94% compared to Fox Marble's net margin of -282.21%. Cambridge Nutritional Sciences' return on equity of 12.15% beat Fox Marble's return on equity.

Company Net Margins Return on Equity Return on Assets
Cambridge Nutritional Sciences16.94% 12.15% -2.36%
Fox Marble -282.21%-38.15%-10.32%

1.6% of Cambridge Nutritional Sciences shares are owned by institutional investors. Comparatively, 2.2% of Fox Marble shares are owned by institutional investors. 7.8% of Cambridge Nutritional Sciences shares are owned by company insiders. Comparatively, 5.6% of Fox Marble shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Cambridge Nutritional Sciences beats Fox Marble on 8 of the 12 factors compared between the two stocks.

How does Cambridge Nutritional Sciences compare to Curzon Energy?

Curzon Energy (LON:CZN) and Cambridge Nutritional Sciences (LON:CNSL) are both small-cap communication companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

Cambridge Nutritional Sciences has a net margin of 16.94% compared to Curzon Energy's net margin of 0.00%. Cambridge Nutritional Sciences' return on equity of 12.15% beat Curzon Energy's return on equity.

Company Net Margins Return on Equity Return on Assets
Curzon EnergyN/A N/A -272.65%
Cambridge Nutritional Sciences 16.94%12.15%-2.36%

Curzon Energy has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, Cambridge Nutritional Sciences has a beta of 2.101, meaning that its share price is 110% more volatile than the broader market.

Curzon Energy has higher earnings, but lower revenue than Cambridge Nutritional Sciences. Curzon Energy is trading at a lower price-to-earnings ratio than Cambridge Nutritional Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Curzon EnergyN/AN/AN/A-£0.01N/A
Cambridge Nutritional Sciences£8.06M0.53-£3.03M£0.603.02

In the previous week, Curzon Energy's average media sentiment score of 0.00 equaled Cambridge Nutritional Sciences'average media sentiment score.

Company Overall Sentiment
Curzon Energy Neutral
Cambridge Nutritional Sciences Neutral

1.6% of Cambridge Nutritional Sciences shares are held by institutional investors. 5.3% of Curzon Energy shares are held by company insiders. Comparatively, 7.8% of Cambridge Nutritional Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Cambridge Nutritional Sciences beats Curzon Energy on 9 of the 9 factors compared between the two stocks.

Get Cambridge Nutritional Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CNSL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNSL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CNSL vs. The Competition

Export
MetricCambridge Nutritional SciencesMedical Instruments & Supplies IndustryMedical SectorLON Exchange
Market Cap£4.31M£2.84B£6.32B£2.79B
Dividend YieldN/A2.03%2.69%6.13%
P/E Ratio3.0216.3921.04364.81
Price / Sales0.5372.26561.9987,608.26
Price / CashN/A146.5442.3127.85
Price / Book0.452.329.837.74
Net Income-£3.03M£99.80M£3.56B£5.88B
7 Day Performance-9.50%0.74%-0.44%6.68%
1 Month Performance-17.73%4.16%4.58%9.92%
1 Year Performance-41.82%-6.68%27.58%75.85%

Cambridge Nutritional Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CNSL
Cambridge Nutritional Sciences
N/AGBX 1.81
-4.7%		N/A-39.1%£4.31M£8.06M3.023,200
CEL
Celadon Pharmaceuticals
N/AGBX 13.40
flat		N/AN/A£8.22M£123.38KN/A2,780
BCE
Beacon Energy
N/AGBX 2.70
-15.6%		N/A+79,900.0%£3.37MN/AN/A44,600
OTT
Oxford Technology 3 Venture Capital Trust
N/AN/AN/AN/A£2.13M-£85KN/A203
FOX
Fox Marble
N/AGBX 0.03
+16.0%		N/A-7.3%£1.01MN/AN/A10,600

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CNSL) was last updated on 6/3/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel